(Q46931556)

English

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

scientific article published on 15 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

phase II clinical trial

0 references

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Suzanne Kamel-Reid

object named as

Suzanne Kamel-Reid

4

0 references

author name string

David A Macdonald

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Sarit E Assouline

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Joseph Brandwein

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Elizabeth A Eisenhauer

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Stephen Couban

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Stephen Caplan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Alison Foo

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Wendy Walsh

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Brian Leber

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

publication date

15 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

54

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

760-766

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Treatment of older patients with acute myeloid leukemia--new agents

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.737917

21 January 2018

Identifiers

10.3109/10428194.2012.737917

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/23061485

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46931556&oldid=1749504067"